ImmuCell (NASDAQ:ICCC) Announces Quarterly Earnings Results
ImmuCell (NASDAQ:ICCC) reported a quarterly loss of $0.02 per share, with a return on equity of 6.25% and a net margin of 6.23%. The stock price fell by $0.08 to $6.05. Weiss Ratings downgraded the stock to a 'sell' rating. Geode Capital Management increased its stake in the company by 4.2% in the second quarter. ImmuCell focuses on animal health products for dairy and beef cattle.
ImmuCell (NASDAQ:ICCC - Get Free Report) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.
ImmuCell Price Performance
ICCC traded down $0.08 during trading on Thursday, reaching $6.05. The company's stock had a trading volume of 6,393 shares, compared to its average volume of 18,710. The company has a market cap of $54.73 million, a price-to-earnings ratio of 31.84 and a beta of 0.29. The firm has a fifty day simple moving average of $6.21 and a two-hundred day simple moving average of $6.23. ImmuCell has a 1 year low of $3.38 and a 1 year high of $7.60. The company has a quick ratio of 1.99, a current ratio of 3.85 and a debt-to-equity ratio of 0.28.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered ImmuCell from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, ImmuCell currently has a consensus rating of "Sell".
Get Our Latest Stock Report on ImmuCell
Hedge Funds Weigh In On ImmuCell
An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC raised its stake in ImmuCell Corporation (NASDAQ:ICCC - Free Report) by 4.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 71,852 shares of the biotechnology company's stock after buying an additional 2,907 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 at the end of the most recent quarter. 13.47% of the stock is owned by institutional investors.
About ImmuCell
(Get Free Report)ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Stories
- Five stocks we like better than ImmuCell
- What is the MACD Indicator and How to Use it in Your Trading
- dLocal Falls Despite Blowout Q3 Results—What Investors Are Missing
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Ondas Holdings Signals a Rebound as Drone Demand Soars
- How Technical Indicators Can Help You Find Oversold Stocks
- Disney’s 2026 Outlook Brightens Under Iger's Magic Touch
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in ImmuCell Right Now?
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
